



Personalized Protocols With Standardized Success

Enabling Protocol Optimization Solutions

The benefits of individualizing

Individualizing contrast protocols can deliver important benefits in image consistency and managing study complexity. Standardizing and easing implementation of personalized protocols can assist in:

- Facilitating implementation of multiple CT abdomen protocol strategies
- Reducing occurrences of sub-optimal CT pulmonary angiography studies¹
- Managing cardiac imaging complexity

Certepra® P3T® software supports healthcare professionals in each of these areas.

P3T software guides technologists in consistently optimizing patient-specific protocols while incorporating radiologist preferences with ease.

Facilitate protocol adherence

Certepra® P3T® 2.0 software guides technologists in individually optimizing contrast-injection protocols tailored to patient weight and study type at the point of care. The software extends established P3T protocol personalization capabilities to allow for improved protocol adherence.


Specifically, technologists can:

- Pre-set radiologist-preferred dosing strategies, contrast concentrations and scan timing
- Recall up to 250 stored protocols

Personalization with Ease

Point-of-care protocol optimization

Powered by the Medrad® Stellant® injection system with Certepra® Workstation, P3T 2.0 calculates individually-optimized patient protocols for CT cardiac, pulmonary angiography and abdomen (liver, pancreas and kidney) studies. Touchscreen prompts guide technologists in accounting for patient and study variables at the point of care.



Images courtesy of the University of Pittsburgh Medical Center (UPMC). Used by Permission.

Certepra® P3T® for PA Software

Pulmonary Angiography – CT Angiography of the pulmonary vasculature

When compared to standard protocol, P3T PA software results in a higher percentage of exams ranked diagnostic without limitation.*^{2,3}


¹ A Clinical Evaluation of an Automated Software Program (Certepra® P3T® PA) for Patient Specific Contrast Injection During Chest CTA to Exclude Pulmonary Embolism; Christopher R Deible MD, PHD, Jacob Alexander MD, Iclal Ocak MD, Maryam Ghadimi Mahani MD, John Kalafut BS, MS, Janet E Durick MD, Carl R Fuhrman MD, Darlene Frasher RN, MSN, Karen M Pealer BA, CCRC, Michael P. Federle MD, Joan M Lacomis MD Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, PA, Medrad, Inc., Pittsburgh, PA RAD-INF-14-06087 May 2014

* Albeit at a slightly higher contrast dose than the standard protocol of 80 ml

² Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible MD, PhD.

³ 510(k) FDA clearance number: K082905.

Image comparison with the same patient



Same patient scanned on two different days:

-Patient weight is 120 lbs.

-Contrast concentration - 350


Images provided during evaluation through the courtesy of Rhode Island Hospital. Used by Permission.

Certepra® P3T® for
Abdomen Software –
CT imaging of the liver,
pancreas and kidneys

Control 1

P3T Group

Control 2



Control Group 1 received 80 mL of contrast media at 6 mL/s.

P3T Group injection parameters were individually adjusted to patient weight, the duration of CT data acquisition, and attenuation parameters following a test bolus.

Control Group 2 the volume of contrast media was adjusted to the duration of CT data acquisition and injected at 5 mL/s.

Images provided through the courtesy of the University of Muenster. Used by Permission.

Certepra® P3T® for
Cardiac Software –
CT Angiography of the cardiac
structures, coronary arteries,
chambers of the heart and
thoracic abdominal aorta



Bayer HealthCare

Radiology
Bayer HealthCare Medical Care

Bayer HealthCare LLC
100 Bayer Boulevard
P.O. Box 915
Whippany, NJ 07981

www.ri.bayer.com



Bayer Medical Care Inc.
1 Bayer Drive
Indianola, PA 15051-0780 USA

Customer Service/Orders
1-800-633-7231

Customer Service Fax
1-412-767-4120

Bayer reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized Bayer HealthCare representative for the most current information.

Bayer, the Bayer Cross, Medrad®, Certepra®, Radimetrics™, and P3T® are trademarks of the Bayer group of companies.

© 2014 Bayer

PP-P3T-US-0001 October 2014